Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/3/2011

#174; and OFIRMEV™ are trademarks of Cadence Pharmaceuticals, Inc.Contact:

William R. LaRue

Kelli KampanisSVP & Chief Financial Officer

Media RelationsCadence Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone:  310-625-3248CADENCE PHARMACEUTICALS, INC.(a development stage company)CONDENSED STATEMENTS OF OPERATIONS(unaudited)(in thousands except per share amounts)Three Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009Operating expenses:Research and development

$
3,192$
4,780$
3,757$
9,464Sales and marketing

11,5976,93926,45511,729General and administrative

3,3663,34212,89212,891Other

31-1,813413Total operating expenses

18,18615,06154,91744,497Loss from operations

(18,186)(15,061)(54,917)(44,497)Other expense, net

(607)(251)(1,726)(994)Net loss

$
(18,793)$
(15,312)$
(56,643)$
(45,491)Basic and diluted net lossper share(1)

$
(0.33)$
(0.30)$
(1.09)$
(0.93)Shares used to compute basic anddiluted net loss per share(1)

56,53150,43052,04248,754(1)  As a result of the issuance of 12,500 shares of common stock pursuant to a public offering in the fourth quarter of 2010 and the issuance of 12,040 shares pursuant to a private placement in the first quarter of 2009, there is a lack of comparability in the per share amounts between the three and twelve month periods presented. CADENCE PHARMACEUTICALS, INC.(a development stage company)CONDENSED BALANCE SHEETS(in thousands)December 31,December 31,2010 2009 (unaudited)AssetsCurrent assets:Cash, cash equivalents and short-term investments

$
34,141$
82,006Restricted cash

1501,498Inventory

485-Prepaid expenses and other current assets

1,268549Total current assets

136,04484,053Property and equipment, net

8,9868,300Intangible assets

15,000-Restricted cash

190190Other assets

'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 31st Annual Health Care Conference in Boston on March 9, 2011
2. Cadence Pharmaceuticals to Present at Two Investment Conferences in February 2011
3. AccessClosure Announces Launch of New Mynx Cadenceā„¢ Vascular Closure Device
4. Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2010 Financial Results on November 5, 2010
7. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
8. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
9. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
10. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
11. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Confirms Effectiveness of Autologous Therapy, DUSSELDORF, ... a two-year,representative study of knee osteoarthritis, published ... confirm,the safety and effectiveness of Orthokine therapy, ... own blood are,injected into the arthritic joint., ...
... Phase III Study to Explore the Effects of ... Calcitonin on Vertebral Fractures in Postmenopausal Women, ... (Nasdaq: EMIS ) announced today that Novartis ... III study exploring the,safety and efficacy of Salmon ...
Cached Medicine Technology:Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years 2Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment 2
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ) as,its ... announced transaction,between Takeda Pharmaceutical Company Limited and Alnylam. ... of future milestone and royalty,payments. This transaction further ...
... of almonds closer to that of roses or bananas? Weizmann ... for the first time that smells can be mapped and ... appeared recently in Nature Methods, may help scientists to unravel ... as potentially enabling odors to be digitized and transferred via ...
... Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) (,Lotus, or the ... China ("PRC"), today,announced that it will conduct a ... May 27, 2008 to discuss the first quarter ... and Chief Executive Officer of Lotus,Pharmaceuticals, will be ...
... ON, May 27 /PRNewswire-FirstCall/ - AlphaRx (OTC ... proprietary drug,delivery technology to develop novel formulations ... and USAMRIID (U.S. Army Medical Research Institute ... Research and,Development Agreement for Material Transfer (MTA). ...
... UCLA have identified a type of leukemia stem cell and ... blood stem cells to become cancerous. , The discovery may ... attacking the disease at its very root and killing the ... The study appears in the May 22, 2008 issue of ...
... Dozens of Videos from Doctors and Students at Seattle Children,s Hospital, Swedish ... ... Available,Videos Offer Insight and Advice on Topics Ranging from Pediatrics to Cancer ... Screening to Novel Surgical Techniques, NEW YORK, May 27 ...
Cached Medicine News:Health News:Isis to Receive $4.6 Million From Alnylam 2Health News:Isis to Receive $4.6 Million From Alnylam 3Health News:Weizmann Institute scientists produce the first smell map 2Health News:Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 3Health News:AlphaRx Signs Cooperative Research and Development Agreement with US Army 2Health News:UCLA researchers identify leukemia stem cells 2Health News:The Doctor's Channel Launches New Videos from Three Top Hospitals 2Health News:The Doctor's Channel Launches New Videos from Three Top Hospitals 3
... The aliquot! The aliquot from Genetix is ... with 96, 384, and 1536 well microplates. ... backfilling facility and optional microplate stacker, the ... low volume dispensing needs. The aliQuot's compact ...
... is a compact and self-contained multichannel ... a unique flow-through device, which allows ... wash system. Optional refill system ... Will be upgradable to with ...
... Aquarius 96 is a compact and self-contained ... fixed tip manifold can be used in ... washed in the optional active wash system. ... dust and adds safety. ...
... ideal system for fast, accurate filling of 96 ... valve controlled dispensing mechanism, ensures that no liquid ... components that come into contact with the liquid ... The unique compact design saves valuable bench space ...
Medicine Products: